UDP-glucuronate decarboxylase 1 promotes tumor immune evasion by accelerating KMT2D loss in hepatocellular carcinoma
Journal for ImmunoTherapy of Cancer · 2026
DOI: 10.1136/jitc-2025-013948 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Jiwei Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: The MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medi…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Tumor Escape, Carboxy-Lyases. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shanghai Pujiang Program, State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Immune checkpoint blockade (ICB) targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis has shown promise in hepatocellular carcinoma (HCC), but clinical responses are often limited in durability. Identifying novel drivers of immune evasion is crucial for improving therapeutic strategies.
Methods
We employed a multi-omics integrative framework to identify HCC-specific immune biomarkers. Functional roles were validated using in vitro and in vivo models, including UDP-glucuronate decarboxylase 1 (UXS1) knockout/overexpression, co-culture assays, and various mouse models. Molecular mechanisms were dissected using immunoprecipitation coupled with mass spectrometry, ubiquitination assays, chromatin immunoprecipitation, luciferase reporter assays, and single-cell RNA sequencing.
Results
We identified the glycosyltransferase UXS1 as a novel immune-related prognostic hub gene in HCC. UXS1 was upregulated due to copy number gain and MZF1-driven promoter hypomethylation. Functionally, UXS1 promoted HCC malignancy independently of its canonical enzymatic activity. Mechanistically, UXS1 interacted with the E3 ligase F-box and WD repeat domain-containing 7 (FBXW7) to promote histone-lysine N-methyltransferase 2D (KMT2D) ubiquitination and degradation. We further discovered that KMT2D, acting as a non-catalytic scaffold, recruited the transcriptional repressor CCAAT enhancer binding protein beta (CEBPB) to the PD-L1 promoter to maintain its repression. UXS1-mediated KMT2D degradation disrupted this complex, leading to CEBPB dissociation and consequent PD-L1 transcriptional derepression. In vivo, UXS1 suppressed CD8 + T-cell effector function. UXS1 knockout synergized with anti-PD-1 therapy, and in human HCC, high UXS1 correlated with low KMT2D, high PD-L1, and reduced CD8 + T-cell infiltration.
Conclusion
This study defines a novel UXS1-KMT2D-CEBPB-PD-L1 signaling axis, revealing how UXS1 drives immune evasion in HCC via epigenetic reprogramming. Targeting this axis may represent a potential strategy to overcome immune resistance, warranting further clinical investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China ding.zhenbin@zs-hospital.sh.cn lzshanghai@163.co…
- State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- The MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Department of Hepatobiliary Surgery and Liver Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of General Surgery, Shanghai Geriatric Medical Center (Zhongshan Hospital Minhang Campus), Fudan University, Shanghai, China.
- Institute for Regenerative Medicine, State Key Laboratory of Cardiology and Medical Innovation Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Förderung
- Shanghai Pujiang Program
- State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine
- National Natural Science Foundation of China
Zitieren
APA
Zhang, J., Li, Y., Chen, J., Ma, F., Feng, B., Zhou, S., Cai, Y., Sun, Y., Gao, Z., Dong, E., Fan, J., Fu, X., Li, Z., & Ding, Z. (2026). UDP-glucuronate decarboxylase 1 promotes tumor immune evasion by accelerating KMT2D loss in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-013948
Vancouver
Zhang J, Li Y, Chen J, Ma F, Feng B, Zhou S, et al. UDP-glucuronate decarboxylase 1 promotes tumor immune evasion by accelerating KMT2D loss in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-013948
BibTeX
@article{Zhang2026,
author = {Zhang, Jiwei and Li, Yuan and Chen, Jiafeng and Ma, Fen and Feng, Ben and Zhou, Shiling and Cai, Yongchao and Sun, Yidi and Gao, Zheng and Dong, Enfu and Fan, Jia and Fu, Xiutao and Li, Zhe and Ding, Zhenbin},
title = {UDP-glucuronate decarboxylase 1 promotes tumor immune evasion by accelerating KMT2D loss in hepatocellular carcinoma},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
doi = {10.1136/jitc-2025-013948}
}
EUVIMED